Investment
Features
FeesSafety
Academy
More
Pluang+

Strive's preferred stock funds $117M Bitcoin buys, now holding 25,000 BTC via innovative equity method.

Protocol Fundamentals
25 Sep 2026
Crypto Briefing
View Source
Bullish
Strive's preferred stock funds $117M Bitcoin buys, now holding 25,000 BTC via innovative equity method.

Strive, Inc. uses its Variable Rate Series A Perpetual Preferred Stock (SATA) to buy Bitcoin without debt or heavy dilution. Since launching SATA in November 2025, the company has raised over $1 billion in notional value and purchased about 25,000 BTC worth over $145 million by issuing new shares when prices trade near par value. This method avoids debt risks and offers a new model for Bitcoin treasury management, differing from traditional convertible debt strategies. Strive's approach shows how preferred equity can sustainably fund large Bitcoin accumulations on public markets.

Strive preferred stock is noted in this context. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Sep 26, 2026 04:21 WIB: Among 50 major cryptocurrencies, 36 rose and 13 fell today. Chainlink (LINK) rose 4.64% to Rp246.855 with a typical hold time of 63 days and 79% buy orders. Aave (AAVE) increased 4.30% to Rp2.712.764 with a 105-day hold time and 73% buy orders. Solana (SOL) gained 4.04% to Rp2.169.267 with a 70-day hold time and 60% buy orders.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
2 hours ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
2 hours ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
3 hours ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
4 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App